GlassScriptPhysician profile
Ernest William Beasley
NPI 1467562959
$14,354.11
in general payments reported to CMS, 2019-2025
51 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $1,257 · 2021: $2,162 · 2022: $2,638 · 2023: $2,324 · 2024: $2,106 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,675 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,675.46 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,185.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,870.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,262.65 | 2019-2025 | Evenity, Tepezza, Prolia |
| Sanofi-Aventis U.S. LLC | $1,040.27 | 2019-2025 | |
| Ibsa Pharma INC. | $831.71 | 2019-2025 | Tirosint, Licart, Tirosint |
| Tandem Diabetes Care, INC. | $619.62 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $599.40 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $583.82 | 2019-2025 | Synthroid |
| Xeris Pharmaceuticals, INC. | $538.72 | 2021-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.27 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Corcept Therapeutics | $491.15 | 2019-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $476.92 | 2019-2025 | Unithroid |
| Dexcom, INC. | $403.59 | 2019-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $279.11 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $249.98 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Beasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.